Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports

Mitsuru Otsubo1,2, Reiko Kinouchi1,3*, Takayuki Kamiya1 and Akitoshi Yoshida1

Abstract

Background: Cystoid macular edema is a rare, vision-threatening side effect of the taxane family of anticancer agents. There is no established treatment or standard treatment protocol for taxane-related cystoid macular edema. Here, we report two cases of taxane-related cystoid macular edema that were treated with topical dorzolamide.

Case presentation: In case 1, a 72-year-old Japanese woman with bilateral geographic choroiditis reported for a follow-up visit with a complaint of blurred vision in both eyes for 2 months after starting nanoparticle albumin-bound paclitaxel chemotherapy for multiple metastases of her breast cancer. Her best-corrected visual acuity had dropped from 1.2 to 0.9 in the right eye and from 1.0 to 0.4 in the left eye. Fundus examination showed no newly active geographic choroiditis lesion, but optical coherence tomography exhibited cystoid macular edema. We suspected taxane-related cystoid macular edema and terminated nanoparticle albumin-bound paclitaxel, and started topical dorzolamide treatment. Cystoid macular edema nearly resolved within 6 weeks in the right eye and within 10 weeks in the left eye after starting topical dorzolamide treatment. The resolution of cystoid macular edema without leaving a chorioretinal scar after discontinuation of paclitaxel confirmed our initial diagnosis of taxane-related cystoid macular edema. A few inconspicuous cystoid spaces persisted at the parafovea for a year after dorzolamide treatment ended, but regressed after restarting dorzolamide treatment without any side effects. Best-corrected visual acuity improved to 1.2 in the right eye and 1.0 in the left eye. In case 2, a 70-year-old Japanese man, who received nanoparticle albumin-bound paclitaxel for pancreatic cancer with multiple metastases, developed bilateral cystoid macular edema. Best-corrected visual acuity was 0.3 bilaterally. Cystoid macular edema resolved within 5 weeks after stopping nanoparticle albumin-bound paclitaxel and starting topical dorzolamide treatment confirming the diagnosis of taxane-related cystoid macular edema. Nine weeks later, best-corrected visual acuity improved to 0.8 in the right eye and 1.0 in the left eye.

Conclusions: Cystoid macular edema in each case resolved within a few months without any side effects using topical dorzolamide and terminating taxane-based chemotherapy. Topical dorzolamide appears to be a safe and effective treatment option for patients with taxane-related cystoid macular edema whose quality of life is threatened by visual disturbances.

Keywords: Dorzolamide, Nab-paclitaxel, Cystoid macular edema, Optical coherence tomography, Taxane
paclitaxel used for the treatment of malignant tumors such as breast cancer, lung cancer, and pancreatic cancer. Patients treated with nab-PTX experience fewer side effects than those treated with solvent-based paclitaxel, such as hypersensitivity reactions, febrile neutropenia, and fatigue [4].

Cystoid macular edema (CME) is a side effect that has been reported in less than 10% of patients treated with nab-PTX, and it usually affects bilateral central vision. While the causes of taxane-related CME are unclear, subtle capillary leakage and effect of taxane toxicity on Müller cells or the retinal pigment epithelium (RPE) have been suspected to play a role [5–12]. Although several treatment options have been reported for taxane-related CME, including oral carbonic anhydrase inhibitors (CAIs) [10], nonsteroidal antiinflammatory drugs [13], sub-Tenon’s injection of triamcinolone acetonide [14], intravitreal bevacizumab [15], and pentoxifylline [9], their effectiveness in resolution of CME remains to be proven [6–9]. Dorzolamide, a topical CAI available as eye drops, is used to lower the intraocular pressure in glaucoma and ocular hypertension; some reports suggest that topical dorzolamide is also effective against taxane-related CME [11, 12, 15]. Shortening the period of visual disturbance without physical burden can improve the quality of life in patients being treated for malignancy with this drug. Here we report two cases of taxane-related CME that resolved after topical dorzolamide treatment. We also present their optical coherence tomography (OCT) images and describe their clinical course.

Case presentation
Case 1: A 72-year-old Japanese woman with bilateral geographic choroiditis reported to our hospital for a follow-up visit with a complaint of blurred vision after starting nab-PTX. Two months prior, she started receiving chemotherapy with 310 mg nab-PTX (220 mg/m² body surface area) every 3 weeks for breast cancer with bone, pulmonary, and lymph node metastases. She received three treatments with nab-PTX, and visited us 2 weeks after the last dose. She had a history of surgery for thyroid cancer at the age of 53 years and for breast cancer at the age of 58 years. There was no family history of cancer and hereditary ophthalmic disease.

Her best-corrected visual acuity (BCVA) declined from 1.2 to 0.9 (decimal visual acuity measured by Landolt C) in the right eye and from 1.0 to 0.4 in the left eye, as compared with the BCVA at the previous visit. The anterior chamber was clear bilaterally, and fundus examination showed no new geographic choroiditis lesions (Fig. 1). OCT showed CME with loss of foveal depression. No obvious CME was seen at the previous visit (Fig. 1).

Since she was treated with nab-PTX, taxane-related CME was suspected. After consultation with her oncologist, chemotherapy was terminated (Fig. 2A). Because CME persisted for 3 weeks (5 weeks since the last nab-PTX treatment) (Fig. 2B), topical 1% dorzolamide treatment three times daily in both eyes was initiated. CME nearly resolved within 6 weeks in the right eye and within 10 weeks in the left eye after starting topical dorzolamide treatment (Fig. 2C, D); the treatment was then discontinued. Our initial diagnosis of taxane-related CME was confirmed, since CME resolved without chorioretinal scaring and without the administration of immunosuppression therapy.

While BCVA was improved to 1.2 in the right eye and 0.7 in the left eye, en face OCT revealed residual parafoveal cystoid spaces in the left eye that persisted for 4 months after discontinuation of dorzolamide.
Otsubo et al. J Med Case Reports          (2021) 15:355

(Figs. 2A, 3A). Since these cystic spaces persisted for a prolonged duration of time and because there was a concern that they would affect vision, dorzolamide was resumed in the left eye, 1 year after the first course of topical dorzolamide treatment had ended (Figs. 2A, 3B). Three months after treatment, the cystoid spaces regressed, and the BCVA improved to 0.8 in the left eye (Figs. 2A, 3C). We ended treatment after 4 months. No recurrence was observed a year after the dorzolamide treatment ended, and BCVA improved to 1.0 in the left eye.

Case 2: A 70-year-old Japanese man was referred to us with a 1-week history of blurred vision. He had a history of surgery for rectal cancer at 63 years of age. Five months prior, he started receiving nab-PTX plus gemcitabine therapy for pancreatic cancer with hepatic and lymph node metastases. He received 210 mg nab-PTX (125 mg/m² body surface area) and gemcitabine on days 1, 8, and 15, every 4 weeks. After receiving five cycles of nab-PTX plus gemcitabine therapy, nab-PTX was terminated owing to the occurrence of sensory disorder of the limbs; only gemcitabine treatment was continued. He visited us 3 weeks after the last nab-PTX treatment. BCVA was 0.3, and the anterior chambers were clear bilaterally. Fundus examination revealed bilateral CME, and neither retinal hemorrhage nor exudate were observed (Fig. 4). Prominent CME was observed bilaterally. Cystoid macular edema (CME) is observed bilaterally. C Six weeks after topical dorzolamide treatment was started. While CME is almost resolved and the foveal depression is restored in the right eye, CME is still observed in the left eye. D Ten weeks after topical dorzolamide was started. Foveal depression is restored bilaterally, and few cystoid spaces are observed.

We suspected taxane-related CME and initiated topical 1% dorzolamide treatment three times daily in both eyes. CME completely resolved bilaterally at his next visit at 5 weeks after starting dorzolamide treatment (Fig. 5B). Nine weeks later, his BCVA improved to 0.8 and 1.0, in the right and left eye, respectively. At this time, we terminated dorzolamide treatment. At the final visit, 2 months following discontinuation of dorzolamide treatment, there was no evidence of CME. We diagnosed this as a case of taxane-related CME, owing to the resolution of CME after cessation of nab-PTX without any treatment other than topical dorzolamide. He passed away 2 months after the final visit.

Fig. 2. Clinical course of case 1. A Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) are shown, in addition to the administration period of nanoparticle albumin-bound paclitaxel (nab-PTX) and topical dorzolamide. The numbers on the horizontal line show weeks since topical dorzolamide first started. Time points of each OCT images taken are indicated by arrows. B–D Optical coherence tomography (OCT) images before and after topical dorzolamide treatment. A 6-mm horizontal sectional OCT scan (A: DRI OCT Triton, Topcon, Tokyo, Japan; B and C: RTVue XR Avanti, Optovue, Fremont, CA). Upper images are of the right eye and lower images are of the left eye. B OCT image when dorzolamide treatment was started, 3 weeks after the first visit for blurred vision and 5 weeks after the last nab-PTX treatment. Cystoid macular edema (CME) is observed bilaterally. C Six weeks after topical dorzolamide treatment was started. While CME is almost resolved and the foveal depression is restored in the right eye, CME is still observed in the left eye. D Ten weeks after topical dorzolamide was started. Foveal depression is restored bilaterally, and few cystoid spaces are observed.
Discussion and conclusions
In case 1, CME was successfully treated after two courses of topical dorzolamide treatment and after discontinuation of nab-PTX chemotherapy. During the first course, prominent CME resolved within 10 weeks of topical dorzolamide treatment, but a few cystoid spaces persisted for a year after cessation of the first course. These were resolved during the second course of topical dorzolamide treatment. In case 2, the CME was completely resolved within 5 weeks after starting dorzolamide treatment, and the treatment was discontinued 9 weeks later. No recurrence was observed after cessation of topical dorzolamide, and no systemic or apparent topical side effects were observed in either case.

Although initially, we could not entirely exclude the possibility of CME induced by other causes, the clinical course of CME, which regressed following initiation of topical dorzolamide and discontinuation of nab-PTX, indicated that the current cases were of taxane-related CME. Fluorescein angiography would have been performed for differential diagnosis had the CME not been resolved. Fluorescein angiography was considered unnecessary, since the patients’ histories and optical findings had provided sufficient information to start non-invasive treatments. Based on the World Health Organization-Uppsala Monitoring Centre system for standardized case causality assessment and the Naranjo algorithm (score = 6), the current cases were deemed to be “probable” taxane-related CME owing to lack of information on patient outcomes following a nab-PTX rechallenge [16, 17]. We did not consider rechallenging the patients with nab-PTX since it would not have been beneficial for the patients and would have compromised their quality of life.
The natural history of taxane-related CMEs is unknown, as only a limited number of cases have been reported. Therefore, it needs to be surveyed. There are a few published case reports on use of topical dorzolamide to treat taxane-related CME. Ehlers et al. (2012) reported a monocular trial of topical dorzolamide, which resulted in reduction of CME within 2 weeks, suggesting the effectiveness of the drug [11]. Hassall and Andrew (2016) reported a single-eye trial of topical dorzolamide and intravitreal bevacizumab, and the effects of both were shown to be approximately equal [15]. Dwivedi and Tiroumal (2016) reported that when topical dorzolamide treatment for taxane-related CME began 4 weeks after the patient discontinued paclitaxel, the CME resolved within 4 weeks [12]. There are a few reports on spontaneous restoration of the macular structure in taxane-related CME 3–6 months after discontinuation of the drug [6, 8, 9]. The duration of CME resolution in case 2 was 2 months from the last nab-PTX treatment, which was shorter than the reported duration of spontaneous restoration. In addition, some taxane-related CME can still persist after discontinuation of the drug, as in case 1, where a few retinal cystoid spaces persisted for a year after the cessation of the first treatment course. Topical dorzolamide appeared to accelerate CME resolution, and was also effective in treating persistent cystoid lesions induced by taxane. Systemic side effects of topical dorzolamide are rare, and common local side effects such as superficial punctate keratitis and blepharitis are treatable and are resolved with drug discontinuation [18]. Thus, we consider that a trial of topical dorzolamide should be initiated in patients with a diagnosis of clinically significant taxane-related CME.

Although evidence of the effectiveness of topical dorzolamide for taxane-related CME is still lacking, the effectiveness of topical dorzolamide in treating cystic macular spaces has been reported in X-linked retinoschisis [19, 20] and retinitis pigmentosa [21]. Both diseases show little capillary leakage on fluorescein angiography, similar to taxane-related CME. The mechanism of action of CAIs in these diseases may be the inhibition of membrane-bound carbonic anhydrase at the basolateral membrane of the RPE. This decreases the subretinal pH and enhances subretinal and intraretinal fluid resorption of the RPE, thus improving CME [20, 22].

Several hypotheses about the pathogenesis of taxane-related CME have been proposed. Taxane-related CME shows no or minimal leakage on fluorescein angiography, but molecules smaller than fluorescein may still leak and cause CME [6, 7, 14, 23]. Müller cell or RPE toxicity due to the effect of taxane on microtubules has also been proposed [14, 23–26]. Since cystoid spaces persisted, but were not worsened after discontinuation of topical dorzolamide, as suggested by en face OCT in case 1, and because cystoid spaces resolved after restarting topical dorzolamide, we speculated that taxane-related CME was not caused by subtle capillary leakage. Instead, it may be caused by an impaired retinal structure caused by taxane-induced Müller cell toxicity.

In conclusion, we demonstrated two cases in which taxane-related CME resolved after topical dorzolamide treatment and discontinuation of nab-PTX. Based on
these findings, topical dorzolamide appears to be a safe and effective treatment option for taxane-related CME.

Abbreviations
CME: Cystoid macular edema; nab-PTX: Nanoparticle albumin-bound paclitaxel; CATs: Carbonic anhydrase inhibitors; OCT: Optical coherence tomography; BCVA: Best-corrected visual acuity; CMT: Central macular thickness; RPE: Retinal pigment epithelium.

Acknowledgements
The authors would like to thank Editage (https://www.editage.com) for the English language review.

Authors’ contributions
RK and TK managed the patients. MO and RK drafted the initial manuscript, which was modified by TK and Ay. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The data used in the case report are available on reasonable request.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient in case 1 and the patient’s next of kin in case 2 for publication of the two case reports and any accompanying images. Copies of the written consents are available for review by the Editor-in-Chief of this journal.

Competing interests
The authors have no financial or nonfinancial competing interests to declare.

Author details
1Department of Ophthalmology, Asahikawa Medical University, 2-1-1-1 Mido-rigaoka Higashi, Asahikawa, Hokkaido, Japan. 2Wakkanai City Hospital, 4-11-6 Chuuou, Wakkanai, Hokkaido, Japan. 3Medicine and Engineering Combined Research Institute, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 078-8510, Japan.

Received: 25 August 2020 Accepted: 10 June 2021
Published online: 21 July 2021

References
1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665–7.
2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–7.
3. Rowinsky EK. The development and clinical utility of the taxane class of antimitotubule chemotherapy agents. Annu Rev Med. 1997;48:353–74.
4. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Oncol Targets Ther. 2011;4:123–36.
5. ABRAXANE® [package insert]. Summit, NJ: Celgene Corporation. 2013.
6. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126(1):1605–6.
7. Tanaka Y, Bando H, Haru H, Ito Y, Okamoto Y. Cystoid macular edema induced by nab-paclitaxel. Breast Cancer. 2015;22(3):324–6.
8. Bassi E, Loizzi V, Furino C, Martino R, Alessio G, Ettore C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol. 2017;7(2):285–7.
9. Shin CH, Lee YC. Impaired retinal pigment epithelium in paclitaxel-induced macular edema: a case report. Medicine (Baltimore). 2018;97(26): e11229.
10. Meyer KM, Klink T, Ugurel S, Brocker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250(3):463–4.
11. Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond). 2013;27(1):102–4.
12. Dviiedi R, Tirolnal S. Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema. Retin Cases Brief Rep. 2018;12(1):75–9.
13. Yokoe T, Fukuda I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A, et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol. 2017;10(2):605–12.
14. Matsuoka N, Hasebe H, Mayama T, Fukuchi T. Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound-paclitaxel (abraxane). Case Rep Ophthalmol. Med. 2015;2015:181269.
15. Hassall MM, Andrew NH. Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula edema. BHU Case Rep. 2016. https://doi.org/10.1160/bhr-2015-212733.
16. Edwards IR, Birrell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93–102.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
18. Tiuxip® [package insert]. Osaka, Japan: Santen Pharmaceutical Co., Ltd. 2014.
19. Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31(3):195–212.
20. Apushkin MA, Fishman GA. Use of dorzolamide for patients with X-linked retinoschisis. Retina. 2006;26(7):741–5.
21. Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743–5.
22. Wolfsberger TJ, Dmitriev AV, Govardovskii VI. Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol. 1999;97(3–4):261–71.
23. Kanakis M, Georgalas I, Makatsoris T, Pharmakakis N. Taxane induced macular edema: case report and literature review. Case Rep Oncol. 2017;10(2):605–12.
24. Retinal pigment epithelium. CME: Cystoid macular edema; nab-PTX: Nanoparticle albumin-bound paclitaxel; CAIs: Carbonic anhydrase inhibitors; OCT: Optical coherence tomography; BCVA: Best-corrected visual acuity; CMT: Central macular thickness; RPE: Retinal pigment epithelium.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.